ArticleJournal of the American Heart Association2026
Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR-CM), but current US population-based epidemiologic data are lacking. This study aimed to estimate temporal trends and current prevalence and incidence of ATTR-CM in the United States and to describe patient characteristics and the clinical burden.
methodsData from the US Merative MarketScan Medicare Database (2010-2021) and the IQVIA PharMetrics Plus (2016-2023) claims database were assessed. An algorithm using codes for diagnoses and clinical drugs was used to identify patients with ATTR-CM among individuals ≥18 years old. Incidence, prevalence, demographics, comorbidities, medication use, and clinical encounters were assessed annually in cross-sectional cohorts.
resultsThe incidence and prevalence of ATTR-CM became higher over time, particularly in men and older age groups. The incidence per 100 000 person-years was 44.3 (95% CI, 39.4-49.2) in 2021 for the Medicare Database (individuals aged ≥65 years) and 5.4 (95% CI, 5.0-5.8) in 2022 for PharMetrics Plus (individuals aged ≥18 years); the prevalence per 100 000 individuals was 95.8 (95% CI, 89.2-102.4) in 2022 in the Medicare Database and 11.3 (95% CI, 10.8-11.8) in 2023 in PharMetrics Plus. The number of comorbidities and medication use in the year before diagnosis increased over time; the number of clinical encounters in the year before diagnosis was relatively stable.
conclusionsThe incidence and prevalence of ATTR-CM diagnoses have increased in the United States from 2010 to 2023, and the clinical burden among newly diagnosed individuals has become more complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.